Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

NCT05704543 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid Use Disorder

Interventions

DRUG: Buprenorphine Extended-Release Injection

Sponsor

Indivior Inc.